Associated Papers
Identification of an ERCC2 mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing data.
Stojkova O et al.
Biorxiv : the Preprint Server for Biology, 2026
41757092 (PubMed )
Supplement: media-1.pdf
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer.
Börcsök J et al.
The Journal of Clinical Investigation, 2025
40829180 (PubMed )
Supplement: jci-135-186688-s236.xlsx › Figure1CD
ERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer.
Barbour JA et al.
Cell Genomics, 2024
Structure-based pathogenicity relationship identifier for predicting effects of single missense variants and discovery of higher-order cancer susceptibility clusters of mutations.
Wang B et al.
Briefings in Bioinformatics, 2023
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
Li Q et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Genomic characterization of response to chemoradiation in urothelial bladder cancer.
Desai NB et al.
Cancer, 2016
Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.
Kim J et al.
Nature Genetics, 2016
27111033 (PubMed )
Supplement: NIHMS774702-supplement-4.xlsx › COMB-279
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Wang J et al.
Plos One, 2014
25372392 (PubMed )
Supplement: pone.0111694.s006.pdf
Select a paper to view details